Twist Bioscience Corporation (TWST)

USD 44.61

(-7.83%)

Market Cap (In USD)

2.64 Billion

Revenue (In USD)

312.97 Million

Net Income (In USD)

-208.72 Million

Avg. Volume

943.98 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
27.41-60.9
PE
-
EPS
-
Beta Value
1.781
ISIN
US90184D1000
CUSIP
90184D100
CIK
1581280
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Dr. Emily Marine Leproust Ph.D.
Employee Count
-
Website
https://www.twistbioscience.com
Ipo Date
2018-10-31
Details
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.